An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF(V600E) mutation responds to dabrafenib and trametinib: a case report and literature review

BACKGROUND: The pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of NSCLC with rapid progression and poor prognosis, and is resistant to conventional chemotherapy. Most PSC cases have potential targetable genomic alterations. Approximately 7% of PSC patients have BRAF mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Ruoxin, Gong, Jun, Liao, Zhengkai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403232/
https://www.ncbi.nlm.nih.gov/pubmed/37546400
http://dx.doi.org/10.3389/fonc.2023.1220745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403232/
https://www.ncbi.nlm.nih.gov/pubmed/37546400
http://dx.doi.org/10.3389/fonc.2023.1220745

Ejemplares similares